GigaDevice GD32F5HC Series MCU Grand Launch, Advancing High‑Performance Innovation for HMI and IoT Edge Solutions
22.4.2026 16:00:00 EEST | Business Wire | Press release
GigaDevice, a leading global supplier of semiconductor devices, today announced the official launch of the GD32F5HC series 32‑bit general‑purpose microcontrollers. Designed with compact size, high frequency operation, large memory, and strong security, while also offering ultra‑low power consumption and rich peripheral configuration, the new series expands the GD32 Arm® Cortex®‑M33 portfolio and delivers a powerful platform for next‑generation HMI and IoT Edge solutions. Samples, development boards, and full technical documentation are now available to support rapid evaluation and mass‑production deployment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422790734/en/
GigaDevice GD32F5HC Series MCU for HMI and IoT Edge Solutions
High‑Efficiency, Advanced Compute Performance and Integrated Security Delivering a Powerful Competitive Edge.
The GD32F5HC series, built on the Arm® Cortex®‑M33 core, operates at a main frequency of 200 MHz, leveraging the efficient Arm®v8-M architecture, these chips feature an advanced DSP hardware accelerator and a single-precision floating-point unit (FPU) to accelerate real‑time control, and algorithm‑driven application tasks. The series features ultra‑large capacity in comparison to similar products, featuring up to 2048KB Flash, 320KB SRAM, and 32KB I‑Cache, enabling developers with large program storage needs to implement complex algorithms, graphics frameworks, and high‑speed data pipelines with ease. The GD32F5HC series also incorporates a comprehensive set of built in security mechanisms. Featuring a TrustZone®‑enabled architecture delivering hardware‑level security protection and supporting dual‑level access control through MPU and SAU to re-enforce security at the core, the series further extends its protection with dedicated hardware security resources including 2k bits eFuse for security key storage and full suite of cryptographic accelerators including TRNG (true random number generator), SHA, DES/3DES, AES, RSA/DH, and ECC. End‑to‑end protection is supported through secure boot, secure storage, secure debugging, and secure upgrades, ensuring firmware integrity and safeguarding devices throughout their lifecycle, offering an increasingly critical level of security as modern products strive to meet stringent requirements under emerging regulations.
Rich Peripheral Resources and High‑Speed Connectivity at the Heart of Application Versatility
To meet the demands of multi‑application scenarios, the GD32F5HC series integrates a rich set of high-speed peripherals and communications interfaces. It includes 2x SPI/1x I2S, 1x SQPI, 1x QSPI, 2x I2C, 3x USART, and 1x USB FS OTG. QSPI and SQPI interfaces support external PSRAM/Flash memory, with frequencies up to 45MHz for expanded storage capacity. Analog peripherals feature 1x 12‑bit ADC and integrated temperature sensor and IFRP for high‑precision analog signal collection and processing.
A robust timing subsystem provides 1x 16‑bit advanced timer, 2x 32‑bit general timers, 4x 16‑bit general timers, and 1x 16‑bit basic timer, supporting precise waveform generation, motor control, and synchronized multi‑axis operation. System throughput is further enhanced by 8‑channel DMA0/DMA1 and DMAMUX module, ensuring efficient data movement and reduced CPU load.
Low‑Power Design and Universal Adaptability
Engineered for both performance‑driven and battery‑powered applications, the GD32F5HC series integrates multi‑mode power optimization; run mode, 30.56mA; sleep; deep sleep; standby, 3.63uA. The chip operates within a voltage range of 2.7~3.63V and covers a temperature range of -40℃~+105℃ combined with power management features such as POR/PDR, LVD, and BOR. Available in highly compact BGA64, 4×4mm, and QFN56 packages with up to 54 GPIO pins and 8 wakeup IO. Perfectly fitting complex, compact and high-density industrial and consumer applications.
Comprehensive Ecosystem Support for Rapid Development
The GD32F5HC series provides full ecosystem support, including mainstream GUI frameworks with QSPI driven resolution up to 400×400, allowing developers to easily create smooth human‑machine interaction interfaces for display‑centric products.
GigaDevice offers the free GD32 Embedded Builder IDE, GD‑LINK debugging tools, and the GD32 All‑In‑One Programmer, with additional mainstream support from Arm® KEIL, IAR, and SEGGER toolchains to streamline development and accelerate time‑to‑market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260422790734/en/
Contacts
Li Xie, marcom@gigadevice.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom